Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 1,590 Shares of Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 1,590 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total transaction of $48,463.20. Following the completion of the transaction, the insider now directly owns 251,033 shares of the company’s stock, valued at $7,651,485.84. This represents a 0.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.69, for a total transaction of $143,228.80.
• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.94, for a total transaction of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40.

Apogee Therapeutics Stock Up 2.0 %

NASDAQ:APGE opened at $36.14 on Friday. The firm has a market cap of $1.63 billion, a PE ratio of -14.93 and a beta of 2.46. Apogee Therapeutics, Inc. has a 12 month low of $29.10 and a 12 month high of $72.29. The company’s 50-day moving average price is $39.12 and its two-hundred day moving average price is $47.02.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). On average, research analysts expect that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

APGE has been the topic of several research analyst reports. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Wedbush reiterated an “outperform” rating and set a $90.00 target price on shares of Apogee Therapeutics in a research report on Monday, March 3rd. Finally, Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $91.60.

Hedge Funds Weigh In On Apogee Therapeutics

Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of Apogee Therapeutics in the fourth quarter worth about $43,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Apogee Therapeutics in the third quarter valued at approximately $71,000. Optimize Financial Inc bought a new stake in Apogee Therapeutics in the fourth quarter valued at approximately $203,000. Aigen Investment Management LP bought a new stake in Apogee Therapeutics in the fourth quarter valued at approximately $216,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Apogee Therapeutics in the fourth quarter valued at approximately $219,000. 79.04% of the stock is owned by institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.